

## ORIGINAL ARTICLE

# Mild deficits in attentional control in patients with the IGSF1 deficiency syndrome

S.D. Joustra\*†, C.D. Andela\*, W. Oostdijk†, A.S.P. van Trotsenburg‡, E. Fliers§, J.M. Witt†, A.M. Pereira\*, H.A.M. Middelkoop¶\*\* and N.R. Biermasz\*

\*Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, †Department of Pediatrics, Leiden University Medical Center, Leiden, ‡Department of Pediatric Endocrinology, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, §Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, ¶Department of Psychology, Section Health, Medical and Neuropsychology, Leiden University, Leiden, and \*\*Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands

## Summary

**Objective** Male patients with the X-linked IGSF1 deficiency syndrome are characterized by central hypothyroidism, delayed pubertal testosterone rise, adult macroorchidism, variable prolactin deficiency and occasionally transient partial growth hormone deficiency. Thyroid hormone plays a vital role in brain development and functioning, and while most patients receive adequate replacement therapy starting shortly after birth, it is unknown whether this syndrome is accompanied by long-term impaired cognitive functioning. We therefore assessed cognitive functioning in male patients with IGSF1 deficiency.

**Methods** Fifteen adult male patients with IGSF1 deficiency participated in neuropsychological assessment of executive functioning and memory, and completed validated questionnaires on health-related quality of life (HRQoL), mood and fatigue. Results were compared to data from previous studies by our department: 54 healthy controls (76 for the attention task) for the test battery and 191 healthy controls for the questionnaires.

**Results** All patients had central hypothyroidism, and twelve were treated with levothyroxine. Patients performed worse than controls in tasks that required attentional control (Trail Making Test, Letter-Digit Substitution Test, and Sustained Attention to Response Task) (all  $P < 0.001$ ). Memory was unaffected. In addition, patients reported more mental fatigue and reduction of activity (Multidimensional Fatigue Inventory) (both  $P < 0.01$ ), while HRQoL and mood reports were not different from controls. Age at the start of replacement therapy and current thyroxine levels were not related to outcome.

**Conclusions** Adult male patients with IGSF1 deficiency exhibit mild deficits in attentional control on formal testing. This

finding was not related to the age at start of replacement therapy, or current levothyroxine treatment.

(Received 10 August 2015; returned for revision 2 September 2015; finally revised 10 September 2015; accepted 15 September 2015)

Loss of function of the immunoglobulin superfamily member 1 (IGSF1) gene causes an X-linked endocrine syndrome in males, characterized by congenital central hypothyroidism, a delayed pubertal testosterone rise despite normal timing of testicular enlargement, adult macroorchidism, and in some cases prolactin or transient partial growth hormone (GH) deficiency.<sup>1,2</sup>

Thyroid hormone plays a vital role in brain development and functioning, and an altered thyroid hormone state has been associated with abnormal cognitive functioning in children and adults.<sup>3</sup> Although many aspects of endocrine dysfunction in IGSF1 deficiency have been studied, cognitive functioning was not assessed. In our experience, patients with IGSF1 deficiency often report attention problems in daily life, *for example* while studying for exams, playing sports like tennis and even when having a conversation. These problems had been present for as long as they could remember and were often recognized by relatives and treating physicians. Indeed, five of the 32 male patients with IGSF1 deficiency currently known to our group, who are all younger than 25 years, had been diagnosed with attention-deficit disorder (ADD), and two of them had been treated with psychostimulants (unpublished data). In addition to these observations, the penetrance of levothyroxine in target tissues in this genetic syndrome has been doubted.<sup>4</sup>

This study aimed to investigate cognitive functioning, specifically executive functioning and memory, in adult male patients with the X-linked IGSF1 deficiency syndrome. Patients were invited for neuropsychological examination, and completed validated questionnaires assessing health-related quality of life

Correspondence: Sjoerd D. Joustra, Department of Medicine, Leiden University Medical Center, POB 9600, 2300RC Leiden, The Netherlands. Tel.: +31715268177; Fax: +31715248136, E-mail: s.d.joustra@lumc.nl

(HRQoL), mood and fatigue. Results were compared to healthy controls.

## Subjects and methods

### Design

Cognitive functioning was assessed in 15 patients with documented IGSF1 deficiency. The neuropsychological examination started at 9:00 AM, and patients were instructed not to drink coffee that morning. During the week following the examination, the patients completed several questionnaires at home assessing HRQoL, mood and fatigue. Cognitive performance and questionnaire scores of patients were compared to control data from previous studies performed in our institution using similar protocols.

### Patients and healthy controls

Inclusion criteria were Dutch male patients between 18 and 75 years old with documented pathogenic mutations in *IGSF1* ( $n = 18$ ). Pathogenicity was based on the presence of central hypothyroidism, phenotype–genotype segregation, and *in silico* and *in vitro* pathogenicity of the mutated proteins, as previously described.<sup>1</sup> Three patients chose not to participate because of long travelling distance; thus, we included 15 patients with IGSF1 deficiency. Results were compared to data from healthy male controls between 18 and 75 years old: for the cognitive tasks from 54 subjects,<sup>5–7</sup> for the sustained attention to response task (SART) from 76 subjects<sup>7,8</sup> and for the questionnaires from 191 subjects.<sup>9</sup>

### Methods

**Cognition – executive functioning.** The Trail Making Test involves scanning, visuomotor tracking, divided attention and cognitive flexibility. The patient has to connect digits with each other (Trail A), followed by connecting digits and letters (Trail B). The time that was used for each trail was noted, with more time used indicating lower performance.<sup>10</sup>

The Stroop Color-Word Test was used to measure interference sensibility. One response (reading the word) should be inhibited in order to name the colour of the ink, which leads to a delay in reaction time.<sup>11</sup> The number of correct responses within 45 s was counted.

The Letter-Digit Substitution Test measures visual scanning, cognitive flexibility, sustained attention, psychomotor speed and speed of information processing.<sup>12</sup> The number of letters correctly substituted for digits within 60 s was counted.

The FAS Test was used to assess verbal mental flexibility and fluency by testing the ability to produce as many words as possible with a specific starting letter (F, A or S).<sup>13</sup> The number of correctly produced words within 60 s was counted.

The Sustained Attention to Response Task (SART) is a test of attentional control assessing both attentional and inhibitory processes by addressing the capacity to attend to a situation or task

in spite of distractibility, fatigue or boredom.<sup>14</sup> After a practice run, numbers from 1 through 9 appeared in random order and in different sizes in a white font on a black computer screen for 4 min and 20 s, 225 times in all. Participants were asked to press a button in response to the appearance of each number, except when the number was a '3', which occurred 25 times. Participants were instructed to give equal importance to accuracy and speed in performing the task. The primary outcome was the total number of errors, consisting of errors of commission (i.e. pressing after a '3') and errors of omission (i.e. not pressing after any number but a '3'). A secondary outcome measure was reaction time (i.e. the response time after the appearance of a number) and variability in reaction time. The test took place in solitude in a quiet room. The SART was performed two times to correct for the learning effect, and only the second run was used.<sup>14</sup> The time in between was spent on other tests (Rey Complex Figure, FAS, Letter-Digit Substitution Test, Stroop Color-Word Test).

**Cognition – memory.** The Wechsler Memory Scale (WMS) was used to assess learning, memory and working memory using auditory and visual stimuli. Higher scores reflect better memory performance.<sup>15</sup>

The Verbal Learning Test of Rey measures verbal memory and learning and consists of three trials in which fifteen words are presented visually. In addition, there is a fourth delayed reproduction. The number of correctly recalled words was counted for each trial. Producing more words in each trial indicates a better learning capacity.<sup>16</sup>

The Rey Complex Figure is a drawing and visual memory test and measures visual-motor organization by examining the ability to copy and remember a complex figure. Immediate recall and delayed recall are measured, and higher scores indicate better visual memory.<sup>17</sup>

**Questionnaires.** The Short Form-36 (SF-36) assesses general well-being and functional status during the previous 30 days.<sup>18</sup> The SF-36 contains nine dimensions, and scores are expressed on a 0–100 range. Because the HADS and the MFI-20 are more specific for mental health and fatigue, assessment of the dimensions 'vitality' and 'general mental health' from the SF-36 was not performed. Because the nine scales are scored separately from exclusive item-specific questions, the results of the scales presented in this study are not influenced by the two dimensions that were left out in this evaluation. Scores are expressed on a 0–100 scale, higher scores being associated with better quality of life.

The Hospital Anxiety and Depression Scale (HADS) assesses anxiety and depressive symptoms.<sup>19</sup> Scores range from 0 to 21, with higher scores indicating more complaints.

The Multidimensional Fatigue Inventory (MFI-20) assesses fatigue in five dimensions.<sup>20</sup> Dimension scores vary from 0 to 20, with higher scores reflecting greater fatigue.

**Laboratory measurements.** Free T<sub>4</sub>, prolactin, cortisol and testosterone levels were measured by electrochemoluminescent immunoassays (ECLIA), using a Modular E170 (Roche

Diagnostics, Mannheim, Germany). The maximal interassay coefficient of variation (CV) for these hormones was 5.0%. Serum IGF-I concentrations in nmol/l were measured using an iSYS immunoanalyser of IDS GMBH in Frankfurt am Main, Germany. The IGF-I assay is standardized against the first international standard 02/254. The intra-assay CV values at mean plasma levels of 6.5 and 14 nmol/l were between 62 and 6.8%, respectively. Serum GH was measured on an Immulite 2000 XPI system (Siemens Healthcare Diagnostics, Deerfield, IL, USA). Measured mU/l was converted to µg/l using a division factor of 2.6. Analytical variation at 5 and 25 mU/l were 5.2% and 4.5%, respectively.

### Statistical analysis

Group differences were compared using the two-tailed independent Student's *t*-test or, in case the assumption of normality was not met (Shapiro–Wilk test), the Mann–Whitney *U*-test. Categorical data were compared using the chi-square test or, when the expected cell count was <5, the Fisher's exact test. Linear regression models were used to correct for differences in age and education in the cognitive tasks, age and reaction time in the SART, and age in the questionnaires. To correct for multiple testing, differences were considered statistically significant at  $P < 0.01$ .

## Results

### Clinical characteristics

We included fifteen adult male patients from ten unrelated families (Table 1). Median age was 25.4 years old (range 19.4–67.7 years). All were diagnosed with central hypothyroidism, and twelve of them were on stable levothyroxine replacement. Five patients started levothyroxine treatment shortly after birth, four in childhood, one in adolescence and the remaining two at middle age. The remaining three patients were recently diagnosed in adulthood, did not show overt signs or symptoms of hypothyroidism and were studied in the untreated condition. Eight patients were prolactin deficient, and GH deficiency was present in one patient who was treated with rhGH. One 25-year-old patient was diagnosed with ADD in adolescence. He was treated with psychostimulants while studying for high school graduation, but stopped afterwards because of side effects. Brain MRI was previously performed in five patients, showing a frontoparietal hygroma in one patient (present at birth and treated with a ventriculoperitoneal shunt), but no abnormalities in the others. Exclusion of the patient with ADD and/or the patient with hygroma did not change the results.

All controls were healthy males between 18 and 75 years old. Mean age in controls was generally higher than that in patients; thus, we corrected for age using regression analysis.

### Cognition – executive functioning

Patients performed worse in several executive functioning tasks (Table 2). Compared with controls and corrected for age and

**Table 1.** Clinical characteristics of IGSF1-deficient male patients

	Patients		Reference range
	Mean ± SD or median (IQR)	Range	
<i>n</i>	15		
Age (year)	25.4 (22.9–56.7)	18.9–67.7	
BMI (kg/m <sup>2</sup> )	28.0 ± 5.4	22.1–39.5	
Central hypothyroidism	15		
Free T <sub>4</sub> at diagnosis (%LL)	82.1 ± 10.2	65.8–95.4	>100%
TSH at diagnosis (mU/l)	2.300 ± 1.361	0.800–5.600	0.300–4.800
Levothyroxine replacement	12		
Growth hormone deficiency	1		
RhGH replacement	1		
Free T <sub>4</sub> (pmol/l)	14.3 ± 5.1	7.9–25.7	12.0–22.0
TSH (mU/l)	0.850 ± 0.671	<0.01–2.270	0.300–4.800
IGF-1 (SDS)	1.2 ± 1.5		Age dependent (in-house)
Basal GH (µg/l)	1.1 ± 1.5		0.0–2.8
Prolactin (µg/l)	6.3 ± 4.1		4.0–15.0
Testosterone (nmol/l)	15.7 ± 5.7		8.0–31.0
Cortisol (µmol/l)*	0.394 ± 0.169		0.100–0.600
Testicular volume (SDS)†	3.9 ± 2.2		40

IQR, interquartile range; %LL: percentage of the lower limit of the age-specific reference range. All measurements were taken at the time of the study, except for free T<sub>4</sub> at diagnosis and TSH at diagnosis.

\*Early morning cortisol level.

†Ultrasonographic volume ( $\pi/6 \times \text{length} \times \text{height} \times \text{width}$ ) of largest testis. SDS: standard deviation score.

education, patients were significantly slower in completing both trails A and B of the Trail Making Test (both  $P \leq 0.001$ ), and substituted fewer words within one minute on the Letter-Digit Substitution Test ( $\beta = -7.8$  (SE 2.2),  $P = 0.001$ ).

Furthermore, patients performed markedly worse than controls on the SART (Table 3), as they made more errors of omission ( $P = 0.001$ ) and commission ( $P < 0.001$ ). Variability in reaction time was greater in patients than controls ( $P < 0.001$ ). As patients' reaction time tended to be quicker, possibly influencing the error rates,<sup>14</sup> we corrected for reaction time as well as age, which did not change the results: patients made more than twice as many mistakes as controls (11.8 more mistakes, 95% CI 8.4–15.2). Results were unavailable in one patient due to failure of the device to automatically store results. Neither free T<sub>4</sub> levels, nor age of start of replacement therapy correlated with executive functioning (corrected for age and education).

Patients' performance in the Verbal Fluency Test and Stroop Color-Word test was not different from controls.

Table 2. Cognitive tasks

	Patients	Controls	<i>P</i>	$\beta^*$ (SE)	<i>P</i>
<i>n</i>	15	54			
Age (year)	36.1 $\pm$ 18.8	55.5 $\pm$ 11.8	<b>0.001</b>		
Male gender	15	54	1.000		
Education level†					
High	8 (53%)	18 (33%)	0.138		
Intermediate	6 (40%)	19 (35%)			
Low	1 (7%)	17 (32%)			
Executive functioning					
Verbal fluency test, no. of correct	35.3 $\pm$ 7.8	34.6 $\pm$ 13.4	0.839	−1.2 (4.3)	0.774
Trail making test					
Trail A, time (min)	0.46 $\pm$ 0.13	0.40 $\pm$ 0.21	0.018	0.2 (0.1)	<b>0.001</b>
Trail A, no. of errors	0.4 $\pm$ 0.5	0.2 $\pm$ 0.4	0.083	0.2 (0.1)	0.245
Trail B, time (min)	1.15 $\pm$ 0.51	1.11 $\pm$ 0.53	0.771	0.5 (0.1)	<b>&lt;0.001</b>
Trail B, no. of errors	0.4 $\pm$ 0.5	0.8 $\pm$ 1.2	0.418	0.0 (0.3)	0.932
Letter-digit substitution test					
No. of correct	29.9 $\pm$ 6.6	32.6 $\pm$ 7.4	0.218	−7.8 (2.2)	<b>0.001</b>
No. of errors	0.1 $\pm$ 0.5	0.1 $\pm$ 0.2	0.829	0.1 (0.1)	0.473
Stroop color-word test, interference total	44.7 $\pm$ 10.2	40.1 $\pm$ 9.9	0.033	−3.8 (2.8)	0.190
Memory					
Wechsler memory scale					
MQ	114.6 $\pm$ 15.8	116.3 $\pm$ 14.4	0.700	1.3 (4.7)	0.778
Information	6.0 $\pm$ 0.0	5.9 $\pm$ 0.2	0.350	0.1 (0.1)	0.441
Orientation	5.0 $\pm$ 0.0	5.0 $\pm$ 0.0	1.000	0.0 (0.0)	1.000
Concentration	7.7 $\pm$ 2.1	7.3 $\pm$ 1.8	0.193	−0.5 (0.6)	0.376
Digit span	12.1 $\pm$ 3.8	9.9 $\pm$ 1.6	0.038	1.5 (0.8)	0.062
Logical memory	7.5 $\pm$ 2.8	7.4 $\pm$ 2.7	0.967	−0.7 (0.9)	0.450
Visual memory	12.2 $\pm$ 1.9	9.2 $\pm$ 3.5	<b>0.001</b>	0.9 (1.0)	0.359
Associative learning	16.4 $\pm$ 3.2	16.6 $\pm$ 2.7	0.971	−1.8 (0.9)	0.049
Verbal learning test of Rey					
Imprinting, total no.	5.8 $\pm$ 2.2	5.3 $\pm$ 1.8	0.331	−0.4 (0.6)	0.523
Immediate, total no.	8.9 $\pm$ 2.2	8.6 $\pm$ 2.1	0.644	−0.9 (0.7)	0.181
Immediate 2, total no.	10.5 $\pm$ 2.2	9.8 $\pm$ 2.2	0.286	−0.7 (0.7)	0.364
Delayed, total no.	8.3 $\pm$ 2.8	8.0 $\pm$ 2.8	0.762	−1.2 (0.9)	0.200
Rey complex figure test					
Immediate	24.6 $\pm$ 5.5	20.9 $\pm$ 6.6	0.046	−0.1 (2.0)	0.964
Delayed	23.9 $\pm$ 5.6	20.9 $\pm$ 6.2	0.098	−0.8 (1.9)	0.684

Data represent number (percentage) or mean  $\pm$  SD, unless specified otherwise. \*Linear regression model assessing the effect of disease, corrected for age and education. †Low: primary education (elementary school) and lower secondary education (preparatory secondary education); Intermediate: higher secondary education (higher general continued education, pre-university secondary education) and postsecondary education (intermediate vocational education); High: tertiary education (higher professional education, university). Statistically significant differences ( $P < 0.01$ ) are marked in *bold*.

### Cognition – memory

Memory function was normal in patients, as they performed similar to controls in the WMS, the Verbal Learning Test of Rey and the Rey Complex Figure Test (Table 2). Initial differences between patients and controls in the WMS subscale visual memory did not persist after correction for age and education.

### Questionnaires

Patients reported more mental fatigue and a reduction in activity in the MFI-20 (both  $P < 0.01$ , corrected for age) (Table 4). No significant differences were observed in patients' responses in the SF-36 or HADS. Neither free  $T_4$  levels nor age at start of replacement therapy was associated with outcome after correcting for age.

### Discussion

The present study demonstrates that patients with IGSF1 deficiency have mild deficits in attentional control with preserved memory function. Furthermore, patients reported more mental fatigue and a reduction in activity, while HRQoL and mood estimates were not affected.

Adult patients with IGSF1 deficiency performed worse than controls in tests that primarily assess attentional processes (the Trail Making Test, Letter-Digit Substitution Test and SART). The Trail Making and Letter-Digit Substitution Test are paper-and-pencil speed tests that require perceptual-motor speed or focussed attention to scan and select target information from an array rapidly and efficiently, and make a skilled manual response quickly (also known as 'focus-execute' attention<sup>21</sup>). The SART

**Table 3.** Sustained attention to response task (executive functioning)

	Patients	Controls	<i>P</i> value	$\beta^*$ (SE)	<i>P</i> value
<i>n</i>	14†	76			
Age	36.8 ± 19.3	45.6 ± 12.8	0.072		
Male gender	15	76	1.000		
Errors of omission	6.0 ± 6.6	0.9 ± 1.8	<b>0.001</b>	4.7 (0.9)	<b>&lt;0.001</b>
Errors of commission	18.8 ± 3.5	10.2 ± 4.8	<b>&lt;0.001</b>	7.0 (1.2)	<b>&lt;0.001</b>
Total no. of errors	24.8 ± 9.2	11.1 ± 5.9	<b>&lt;0.001</b>	11.8 (1.7)	<b>&lt;0.001</b>
Mean RT (ms)	250.8 ± 45.2	277.3 ± 42.8	0.082		
RT variability (ms)	138.2 ± 69.0	69.1 ± 27.1	<b>&lt;0.001</b>		

Data represent mean ± SD or beta coefficient (SE). \*Linear regression model assessing the effect of disease, corrected for age and reaction time.

†Results from one patient were unavailable. RT, reaction time. Statistically significant differences ( $P < 0.01$ ) are marked in **bold**.

**Table 4.** Questionnaires on health-related quality of life, mood and fatigue

	Patients	Controls	<i>P</i> value	$\beta^*$ (SE)	<i>P</i> value
<i>n</i>	15	191			
Age	36.1 ± 19.0	53.4 ± 12.6	<b>0.001</b>		
Male gender	15	191	1.000		
SF-36					
Physical functioning	91.7 ± 20.2	91.7 ± 12.8	0.290	−6.2 (3.6)	0.084
Social functioning	90.0 ± 17.2	93.7 ± 13.4	0.221	−6.1 (3.9)	0.118
Role physical problem	81.7 ± 38.3	90.5 ± 22.8	0.787	−11.4 (6.8)	0.098
Role emotional problem	82.2 ± 33.0	91.7 ± 22.4	0.206	−9.1 (6.6)	0.170
Pain	89.6 ± 22.7	89.6 ± 14.9	0.958	−6.0 (4.4)	0.164
General health perception	76.3 ± 21.3	73.9 ± 15.8	0.238	−3.4 (4.5)	0.442
Health change	55.0 ± 19.4	53.4 ± 16.1	0.727	−0.7 (4.7)	0.881
HADS					
Anxiety	4.4 ± 3.6	3.2 ± 2.5	0.285	0.9 (0.7)	0.229
Depression	2.8 ± 3.4	2.6 ± 2.7	0.839	0.9 (0.8)	0.244
Total	7.2 ± 6.8	5.8 ± 4.3	0.787	1.8 (1.3)	0.170
MFI-20					
General fatigue	9.4 ± 4.3	7.4 ± 3.5	0.054	1.7 (1.0)	0.086
Physical fatigue	7.8 ± 4.5	7.2 ± 3.3	0.880	1.3 (1.0)	0.172
Reduction in activity	9.3 ± 4.3	7.0 ± 3.1	0.019	2.7 (0.9)	<b>0.003</b>
Reduction in motivation	7.7 ± 3.6	6.9 ± 3.1	0.394	1.0 (0.9)	0.255
Mental fatigue	12.0 ± 5.2	7.1 ± 3.2	<b>&lt;0.001</b>	4.8 (1.0)	<b>&lt;0.001</b>

Data represent mean ± SD or beta coefficient (SE). \*Linear regression model assessing the effect of disease, corrected for age. Statistically significant differences ( $P < 0.01$ ) are marked in **bold**.

was designed to test sustained attention, that is the capacity to maintain focus and alertness over time (also known as ‘vigilance’<sup>21</sup>). However, the SART also requires focussed attention and inhibition (withholding a pre-potent response,<sup>21</sup> for example commission errors), and the Trail Making and Letter-Digit Substitution Test also require sustained attention,<sup>21</sup> as all of these attentional processes are highly interdependent. We therefore chose to classify the observed alterations using the overarching construct of top-down control or co-ordination of action within the network of structures responsible for complex goal-oriented behaviour known as ‘attention control’.<sup>22</sup>

The Stroop Color-Word Test also requires attentional control.<sup>21</sup> Although patients performed slightly worse than controls in this test, differences were not statistically significant. This

inconsistency with the Trail Making and Letter-Digit Substitution Test might be explained by the required response being verbal rather than manual. Mental flexibility (Verbal Fluency Test) was normal.

Reductions in attentional control were also experienced subjectively by patients, as they reported more problems in the MFI-20 subscales mental fatigue (i.e. ‘When I am doing something, I can keep my thoughts on it/My thoughts easily wander’ and ‘I can concentrate well/It takes a lot of effort to concentrate on things’) and reduction in activity (i.e. ‘I feel very active’ and ‘I think I do a lot in a day/I think I do very little in a day/I get little done’). As patients reported no disturbances of general and physical fatigue in the MFI-20, nor of physical functioning in the SF-36, the observations are unlikely explained by physical



tiredness. These complaints may be a consequence of the deficits in attentional control, or share a common aetiology with these deficits.

Nevertheless, the clinical significance of the observations for patients is hard to assess. As IGSF1 deficiency is congenital, functioning cannot be compared to a predisease state. Furthermore, attention was sufficient to perform well in tasks of memory in the WMS, the Verbal Learning Test of Rey and the Rey Complex Figure Test, as well as mental flexibility in the Verbal Fluency Test. Also, while some reported problems with concentrating during consultations, most patients did not consult a professional for complaints of attentional control, educational level was normal and matched current profession, and differences with the controls' mean were often less than two standard deviations scores (Trail Making Test:  $1.0 \pm 0.3$  SDS, Letter-Digit Substitution Test:  $1.1 \pm 0.3$  SDS, SART errors of omission:  $2.6 \pm 0.5$  SDS and commission:  $1.5 \pm 0.3$  SDS, MFI-20 reduction in activity:  $0.9 \pm 0.3$  SDS and mental fatigue:  $1.5 \pm 0.3$  SDS). We therefore consider the symptoms to be mild.

Our results are in good accordance with several studies in children with (early treated) congenital hypothyroidism that report disturbances of especially the attention components focussed attention, inhibition and sustained attention,<sup>23–25</sup> especially in those with prematurity or the lowest plasma or serum T<sub>4</sub> concentrations in the neonatal period.<sup>26–28</sup> Therefore, the difficulties with attentional control in patients with IGSF1 deficiency might be related to inadequate (prenatal) T<sub>4</sub> concentrations during critical periods of brain maturation, rather than to abnormal T<sub>4</sub> concentrations in adulthood. This is supported by the absence of a correlation between executive functioning and either free T<sub>4</sub> concentrations or age of start of replacement therapy in the IGSF1-deficient patients. Moreover, adults with acquired primary hypothyroidism usually report symptoms of anxiety and depression (which were not present in patients with IGSF1 deficiency), and rarely present with problems in the cognitive domain,<sup>29</sup> although some studies reported impaired (sustained) attention in patients treated for autoimmune hypothyroidism while not in other causes of acquired primary hypothyroidism.<sup>30,31</sup> On the other hand, direct effects of IGSF1 on adult executive functioning cannot be excluded, as IGSF1 is expressed in the adult rat cerebral cortex, striatum, subfornical organ, amygdala and in glial cells of the hypothalamus.<sup>32</sup> Although IGSF1's function in these brain regions is still unknown, other members of the Ig superfamily are involved in the development and maintenance of various parts of the central nervous system.<sup>33,34</sup>

Of special interest are patients with generalized resistance to thyroid hormone (GRTH), a disorder caused by mutations in the thyroid hormone receptor beta (THRB) gene, characterized by reduced responsiveness of peripheral and pituitary tissues to thyroid hormone. Forty-eight to 73% of these patients have been found to show attention-deficit/hyperactivity disorder.<sup>35</sup> Several studies confirmed the relation between this defect and especially sustained attention and ADD, which might be related to higher glucose metabolism in the right parietal cortex and anterior cingulate gyrus.<sup>36</sup> Treatment with liothyronine sodium, and not

levothyroxine, improved these complaints.<sup>37</sup> Moreover, TRB knockout mice show disturbances of sustained attention and are used as a model for ADD.<sup>38</sup> In our adult patient group, we observed no relation between outcome and T<sub>4</sub> concentrations at the time of evaluation or the age of start replacement therapy, raising the question whether the current treatment in these patients is sufficient. The pathophysiology of IGSF1 deficiency is still unresolved, but given the similarities with GRTH, it would be interesting to treat these patients with liothyronine and re-evaluate cognitive functioning.

Besides congenital central hypothyroidism, a number of patients with IGSF1 deficiency exhibit persistent prolactin deficiency or transient partial GH deficiency in childhood. There are no reports of associations between these conditions and vigilance. We also previously reported a frontoparietal hygroma, a small pituitary stalk lesion and hypoplasia of the corpus callosum in three of eleven brain MRI studies in IGSF1-deficient patients.<sup>1</sup> Associations between callosal efficiency and vigilance have been reported.<sup>39</sup> However, as the integrity of the corpus callosum was normal in all other MRI's, callosal inefficiency is unlikely to explain the profound disturbances observed in patients with IGSF1 deficiency.

An obvious limitation of this study is its small group size, which is inherent to the low prevalence of IGSF1 deficiency. A second limitation is that we did not include a matched control group. However, we were able to select large groups of controls that were studied with similar protocols in our institution, and corrected for differences in age or education level. We contend that the observations are both clear and informative.

In conclusion, this first study on cognitive functioning of adult male patients with the X-linked IGSF1 deficiency syndrome showed that these patients exhibit mild deficits in attentional control with preserved memory function. Furthermore, patients reported more mental fatigue and reduced activity. These results resemble findings in other congenital disorders involving thyroid hormone, especially GRTH, but were not related to current treatment with levothyroxine or the age at which replacement therapy was initiated. Future research in (juvenile) patients and animal models is needed to further elucidate whether these deficits are caused by irreversible damage from intra-uterine hypothyroxinaemia, or whether they are related to decreased sensitivity to treatment with levothyroxine. Either way, physician awareness of the presence of these deficits in patients with IGSF1 deficiency may be helpful during consultations. If necessary, neuropsychological interventions or treatment with psychostimulants may be considered.

## Acknowledgements

We thank all patients for their participation, and Dr. J. Tjemmesma, Dr. M. van Dijk and Dr. A.A. van der Klaauw for providing the control data.

## Disclosure statement

Nothing to declare.

## References

- 1 Sun, Y., Bak, B., Schoenmakers, N. *et al.* (2012) Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. *Nature Genetics*, **44**, 1375–1381.
- 2 Joustra, S.D., Schoenmakers, N., Persani, L. *et al.* (2013) The IGSF1 deficiency syndrome: characteristics of male and female patients. *Journal of Clinical Endocrinology and Metabolism*, **98**, 4942–4952.
- 3 Nandi-Munshi, D. & Taplin, C.E. (2015) Thyroid-related neurological disorders and complications in children. *Pediatric Neurology*, **52**, 373–382.
- 4 Joustra, S.D., Roelfsema, F., Endert, E. *et al.* (2015) Pituitary hormone secretion profiles in IGSF1 deficiency syndrome. *Neuroendocrinology*, In press.
- 5 Tiemensma, J., Biermasz, N.R., van der Mast, R.C. *et al.* (2010) Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **95**, E392–E402.
- 6 Tiemensma, J., Kokshoorn, N.E., Biermasz, N.R. *et al.* (2010) Subtle cognitive impairments in patients with long-term cure of Cushing's disease. *Journal of Clinical Endocrinology and Metabolism*, **95**, 2699–2714.
- 7 Tiemensma, J., Andela, C.D., Biermasz, N.R. *et al.* (2015) Mild cognitive deficits in patients with primary adrenal insufficiency. *Psychoneuroendocrinology*, In press.
- 8 van Dijk, M., Donga, E., Van Schie, M.K. *et al.* (2014) Impaired sustained attention in adult patients with type 1 diabetes is related to diabetes per se. *Diabetes Metabolism Research and Reviews*, **30**, 132–139.
- 9 van der Klaauw, A.A., Kars, M., Biermasz, N.R. *et al.* (2008) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. *Clinical Endocrinology (Oxford)*, **69**, 775–784.
- 10 Reitan, R. (1956) Trail making test: manual for administration, scoring, and interpretation.
- 11 Stroop, J.R. (1992) Studies of interference in serial verbal reactions. *Journal of Experimental Psychology*, **121**, 15–23.
- 12 van der Elst, W., van Boxtel, M.P., van Breukelen, G.J. *et al.* (2006) The Letter Digit Substitution Test: normative data for 1858 healthy participants aged 24–81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. *Journal of Clinical and Experimental Neuropsychology*, **28**, 998–1009.
- 13 Benton, A.L. & Hamsher, K.D. (1976) Multilingual Aphasia Examination.
- 14 Van Schie, M.K., Alblas, E.E., Thijs, R.D. *et al.* (2014) The influences of task repetition, napping, time of day, and instruction on the Sustained Attention to Response Task. *Journal of Clinical and Experimental Neuropsychology*, **36**, 1055–1065.
- 15 Wechsler, D. & Stone, C.P. (1945) Wechsler Memory Scale.
- 16 Rey, A. (1958) L'examen Clinique en Psychologie.
- 17 Rey, A. (1941) L'examen psychologique dans les cas d'encephalopathie traumatique. *Archives of Psychology*, **28**, 286–340.
- 18 Brazier, J.E., Harper, R., Jones, N.M. *et al.* (1992) Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ*, **305**, 160–164.
- 19 Zigmond, A.S. & Snaitch, R.P. (1983) The hospital anxiety and depression scale. *Acta Psychiatrica Scand.*, **67**, 361–370.
- 20 Smets, E.M., Garssen, B., Bonke, B. *et al.* (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. *Journal of Psychosomatic Research*, **39**, 315–325.
- 21 Mirsky, A.F., Anthony, B.J., Duncan, C.C. *et al.* (1991) Analysis of the elements of attention: a neuropsychological approach. *Neuropsychology Review*, **2**, 109–145.
- 22 Milham, M.P., Erickson, K.I., Banich, M.T. *et al.* (2002) Attentional control in the aging brain: insights from an fMRI study of the stroop task. *Brain and Cognition*, **49**, 277–296.
- 23 Rovet, J.F. & Hepworth, S. (2001) Attention problems in adolescents with congenital hypothyroidism: a multicomponential analysis. *Journal of the International Neuropsychological Society*, **7**, 734–744.
- 24 Alvarez, M., Iglesias, F.C., Rodriguez, S.A. *et al.* (2010) Episodes of overtreatment during the first six months in children with congenital hypothyroidism and their relationships with sustained attention and inhibitory control at school age. *Hormone Research in Paediatrics*, **74**, 114–120.
- 25 Rovet, J.F. (1999) Long-term neuropsychological sequelae of early-treated congenital hypothyroidism: effects in adolescence. *Acta Paediatrica. Supplement*, **88**, 88–95.
- 26 Kooistra, L., van der Meere, J.J., Vulsma, T. *et al.* (1996) Sustained attention problems in children with early treated congenital hypothyroidism. *Acta Paediatrica*, **85**, 425–429.
- 27 Song, S.I., Daneman, D. & Rovet, J. (2001) The influence of etiology and treatment factors on intellectual outcome in congenital hypothyroidism. *Journal of Developmental and Behavioral Pediatrics*, **22**, 376–384.
- 28 Simic, N., Asztalos, E.V. & Rovet, J. (2009) Impact of neonatal thyroid hormone insufficiency and medical morbidity on infant neurodevelopment and attention following preterm birth. *Thyroid*, **19**, 395–401.
- 29 Ritchie, M. & Yeap, B.B. (2015) Thyroid hormone: Influences on mood and cognition in adults. *Maturitas*, **81**, 266–275.
- 30 Wekking, E.M., Appelhof, B.C., Fliers, E. *et al.* (2005) Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. *European Journal of Endocrinology*, **153**, 747–753.
- 31 Leyhe, T., Mussig, K., Weinert, C. *et al.* (2008) Increased occurrence of weaknesses in attention testing in patients with Hashimoto's thyroiditis compared to patients with other thyroid illnesses. *Psychoneuroendocrinology*, **33**, 1432–1436.
- 32 Joustra, S.D., Meijer, O.C., Heinen, C.A. *et al.* (2015) Spatial and temporal expression of immunoglobulin superfamily member 1 in the rat. *Journal of Endocrinology*, **226**, 181–191.
- 33 Katidou, M., Vidaki, M., Strigini, M. *et al.* (2008) The immunoglobulin superfamily of neuronal cell adhesion molecules: lessons from animal models and correlation with human disease. *Biotechnology Journal*, **3**, 1564–1580.
- 34 Irintchev, A. & Schachner, M. (2012) The injured and regenerating nervous system: immunoglobulin superfamily members as key players. *Neuroscientist*, **18**, 452–466.
- 35 Hauser, P., Zametkin, A.J., Martinez, P. *et al.* (1993) Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. *New England Journal of Medicine*, **328**, 997–1001.
- 36 Matochik, J.A., Zametkin, A.J., Cohen, R.M. *et al.* (1996) Abnormalities in sustained attention and anterior cingulate metabolism in subjects with resistance to thyroid hormone. *Brain Research*, **723**, 23–28.

- 37 Weiss, R.E., Stein, M.A. & Refetoff, S. (1997) Behavioral effects of liothyronine (L-T3) in children with attention deficit hyperactivity disorder in the presence and absence of resistance to thyroid hormone. *Thyroid*, **7**, 389–393.
- 38 Siesser, W.B., Cheng, S.Y. & McDonald, M.P. (2005) Hyperactivity, impaired learning on a vigilance task, and a differential response to methylphenidate in the TRbetaPV knock-in mouse. *Psychopharmacology (Berl)*, **181**, 653–663.
- 39 Rueckert, L., Baboorian, D., Stavropoulos, K. *et al.* (1999) Individual differences in callosal efficiency: correlation with attention. *Brain and Cognition*, **41**, 390–410.
- 40 Joustra, S.D., van der Plas, E.M., Goede, J. *et al.* (2015) New reference charts for testicular volume in Dutch children and adolescents allow the calculation of standard deviation scores. *Acta Paediatrica*, **104**, e271–e278.